NCT04987567View on ClinicalTrials.gov

Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

February 20, 2020

Study Completion Date

February 20, 2020

Conditions
Cystic Fibrosis in Children
Interventions
DIETARY_SUPPLEMENT

ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)

Pearls of DHA (BrudyNen)

DIETARY_SUPPLEMENT

PLACEBO (OLIVE OIL)

Pearls manufactured to mimic DHA (BrudyNen).

Trial Locations (1)

08208

Parc Tauli Hospital, Sabadell

Sponsors
All Listed Sponsors
lead

Corporacion Parc Tauli

OTHER

NCT04987567 - Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients | Biotech Hunter | Biotech Hunter